RB-100 / RenBio - LARVOL DELTA

RenBio Completes $24 Million Series A Financing and Licenses Novel SARS-CoV-2 Bispecific Antibody from Columbia University (PRNewswire) - "RenBio...has completed a $24 million Series A financing, led by Taiwan-based Ruentex Group. The company has also signed a license agreement with Columbia University, giving RenBio the exclusive worldwide development and commercialization rights to a novel bispecific antibody (RB-100) for COVID-19 that was developed in the lab of David D. Ho, M.D. of Columbia University and targets two distinct sites on the spike of SARS-CoV-2. In preclinical studies, RB-100 demonstrated robust antiviral activity against SARS-CoV-2 variants that have recently emerged...Under the license agreement, Columbia University received an equity stake in RenBio...With proceeds from the Series A financing, RenBio is expected to complete IND-enabling preclinical studies and initiate a Phase 1/2 clinical trial of RB-100 in 2021."

Financing • Licensing / partnership • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease